Gary D. Friedman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gary D. Friedman has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Laurel A. Habel
Division of Research Kaiser Permanente Northern California Oakland California USA
10 shared publications Natalia Udaltsova
Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA
6 shared publicationsCharles P. Quesenberry
Division of Research, Kaiser Permanente Medical Care Program, Oakland, USA
5 shared publicationsJames Chan
Pharmacy Outcomes Research Group, Kaiser Permanente Medical Care Program, Oakland, USA
4 shared publications- Arthur L. Klatsky
Senior Consultant in Cardiology and an Adjunct Investigator in the Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA.
1 shared publication - Bentson H. McFarland
Department of Psychiatry, Oregon Health & Science University, Portland, Oregon
1 shared publication
Latest Publications
- Open Access
- 5 July 2016
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 108 (10)
Statins and Reduced Risk of Liver Cancer: Evidence for Confounding: Table 1.
A negative association of statin use with liver cancer risk has been reported frequently. We added laboratory measurements, to our knowledge not included in previous investigations, to a case-control analysis of 2877 case patients and 142 850 matched control subjects enrolled in Kaiser Permanente Northern California. Addressing confounding by indication by restricting subjects to those with elevated cholesterol greatly attenuated the negative association; eg, the multivariable-adjusted odds ratio (OR) rose from 0.41 (95% confidence interval [CI] = 0.35 to 0.49) to 0.87 (95% CI = 0.55 to 1.39) for receipt of 18 or more prescriptions. Confounding by contraindication was addressed by controlling for degree of abnormality of liver function tests, alanine or aspartate transaminase, measured within one year of the elevated cholesterol and strongly related to risk. The negative association of statins disappeared for all numbers of prescriptions received, with an odds ratio of 1.21 (95% CI = 0.53 to 2.75) for 18 or more prescriptions. Findings cast doubt on the causality of the frequently observed preventive association.
- 5 July 2016
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 108 (10)
Open AccessStatins and Reduced Risk of Liver Cancer: Evidence for Confounding: Table 1.
A negative association of statin use with liver cancer risk has been reported frequently. We added laboratory measurements, to our knowledge not included in previous investigations, to a case-control analysis of 2877 case patients and 142 850 matched control subjects enrolled in Kaiser Permanente Northern California. Addressing confounding by indication by restricting subjects to those with elevated cholesterol greatly attenuated the negative association; eg, the multivariable-adjusted odds ratio (OR) rose from 0.41 (95% confidence interval [CI] = 0.35 to 0.49) to 0.87 (95% CI = 0.55 to 1.39) for receipt of 18 or more prescriptions. Confounding by contraindication was addressed by controlling for degree of abnormality of liver function tests, alanine or aspartate transaminase, measured within one year of the elevated cholesterol and strongly related to risk. The negative association of statins disappeared for all numbers of prescriptions received, with an odds ratio of 1.21 (95% CI = 0.53 to 2.75) for 18 or more prescriptions. Findings cast doubt on the causality of the frequently observed preventive association.
- 2 April 2014
- Published by Springer Nature in Cancer Causes & Control
- Vol. 25 (6) , 693-699
Moderate alcohol intake and cancer: the role of underreporting
There is compelling evidence that heavy alcohol drinking is related to increased risk of several cancer types, but the relationship of light–moderate drinking is less clear. We explored the role of inferred underreporting among light–moderate drinkers on the association between alcohol intake and cancer risk. In a cohort of 127,176 persons, we studied risk of any cancer, a composite of five alcohol-associated cancer types, and female breast cancer. Alcohol intake was reported at baseline health examinations, and 14,880 persons were subsequently diagnosed with cancer. Cox proportional hazard models were controlled for seven covariates. Based on other computer-stored information about alcohol habits, we stratified subjects into 18.4 % (23,363) suspected of underreporting, 46.5 % (59,173) not suspected of underreporting, and 35.1 % (44,640) of unsure underreporting status. Persons reporting light–moderate drinking had increased cancer risk in this cohort. For example, the hazard ratios (95 % confidence intervals) for risk of any cancer were 1.10 (1.04–1.17) at <1 drink per day and 1.15 (1.08–1.23) at 1–2 drinks per day. Increased risk of cancer was concentrated in the stratum suspected of underreporting. For example, among persons reporting 1–2 drinks per day risk of any cancer was 1.33 (1.21–1.45) among those suspected of underreporting, 0.98 (0.87–1.09) among those not suspected, and 1.20 (1.10–1.31) among those of unsure status. These disparities were similar for the alcohol-related composite and for breast cancer. We conclude that the apparent increased risk of cancer among light–moderate drinkers may be substantially due to underreporting of intake.
- 2 April 2014
- Published by Springer Nature in Cancer Causes & Control
- Vol. 25 (6) , 693-699
Moderate alcohol intake and cancer: the role of underreporting
There is compelling evidence that heavy alcohol drinking is related to increased risk of several cancer types, but the relationship of light–moderate drinking is less clear. We explored the role of inferred underreporting among light–moderate drinkers on the association between alcohol intake and cancer risk. In a cohort of 127,176 persons, we studied risk of any cancer, a composite of five alcohol-associated cancer types, and female breast cancer. Alcohol intake was reported at baseline health examinations, and 14,880 persons were subsequently diagnosed with cancer. Cox proportional hazard models were controlled for seven covariates. Based on other computer-stored information about alcohol habits, we stratified subjects into 18.4 % (23,363) suspected of underreporting, 46.5 % (59,173) not suspected of underreporting, and 35.1 % (44,640) of unsure underreporting status. Persons reporting light–moderate drinking had increased cancer risk in this cohort. For example, the hazard ratios (95 % confidence intervals) for risk of any cancer were 1.10 (1.04–1.17) at <1 drink per day and 1.15 (1.08–1.23) at 1–2 drinks per day. Increased risk of cancer was concentrated in the stratum suspected of underreporting. For example, among persons reporting 1–2 drinks per day risk of any cancer was 1.33 (1.21–1.45) among those suspected of underreporting, 0.98 (0.87–1.09) among those not suspected, and 1.20 (1.10–1.31) among those of unsure status. These disparities were similar for the alcohol-related composite and for breast cancer. We conclude that the apparent increased risk of cancer among light–moderate drinkers may be substantially due to underreporting of intake.
- Open Access
- 27 November 2010
- Published by Wiley in International Journal of Cancer
- Vol. 128 (3) , 736-738
Norepinephrine antagonists and cancer risk
- 27 November 2010
- Published by Wiley in International Journal of Cancer
- Vol. 128 (3) , 736-738
Open AccessNorepinephrine antagonists and cancer risk
- 7 July 2009
- Published by Springer Nature in Cancer Causes & Control
- Vol. 20 (10) , 1821-1835
Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened
Objective To screen commonly used prescription drugs for possible carcinogenic effects. Methods In a large health care program we identified 105 commonly used drugs, not previously screened. Recipients were followed for up to 12½ years for incident cancer. Nested case–control analyses of 55 cancer sites and all combined included up to ten matched controls per case, with lag of at least 2 years between drug dispensing and cancer. Positive associations entailed a relative risk of 1.50, with p ≤ 0.01 and higher risk for three or more, than for one prescription. Evaluation included further analyses, searches of the literature, and clinical judgment. Results There were 101 associations of interest for 61 drugs. Sixty-six associations were judged to have involved substantial confounding. We found evidence that of the remaining 35, the following associations may not be due to chance: sulindac with gallbladder cancer and leukemia, hyoscyamine with nonHodgkin lymphoma, nortriptyline with esophageal and hepatic cancer, oxazepam with lung cancer, both fluoxetine and paroxetine with testicular cancer, hydrochlorothiazide with renal and lip cancer, and nifedipine with lip cancer. Conclusions These preliminary findings suggest that further studies are indicated regarding sulindac, hyoscyamine, nortriptyline, oxazepam, fluoxetine, paroxetine, hydrochlorothiazide, and nifedipine.
- 7 July 2009
- Published by Springer Nature in Cancer Causes & Control
- Vol. 20 (10) , 1821-1835
Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened
Objective To screen commonly used prescription drugs for possible carcinogenic effects. Methods In a large health care program we identified 105 commonly used drugs, not previously screened. Recipients were followed for up to 12½ years for incident cancer. Nested case–control analyses of 55 cancer sites and all combined included up to ten matched controls per case, with lag of at least 2 years between drug dispensing and cancer. Positive associations entailed a relative risk of 1.50, with p ≤ 0.01 and higher risk for three or more, than for one prescription. Evaluation included further analyses, searches of the literature, and clinical judgment. Results There were 101 associations of interest for 61 drugs. Sixty-six associations were judged to have involved substantial confounding. We found evidence that of the remaining 35, the following associations may not be due to chance: sulindac with gallbladder cancer and leukemia, hyoscyamine with nonHodgkin lymphoma, nortriptyline with esophageal and hepatic cancer, oxazepam with lung cancer, both fluoxetine and paroxetine with testicular cancer, hydrochlorothiazide with renal and lip cancer, and nifedipine with lip cancer. Conclusions These preliminary findings suggest that further studies are indicated regarding sulindac, hyoscyamine, nortriptyline, oxazepam, fluoxetine, paroxetine, hydrochlorothiazide, and nifedipine.
- Open Access
- 27 April 2009
- Published by Wiley in International Journal of Cancer
- Vol. 125 (9) , 2173-2178
Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity
Thorough review by the International Agency for Research on Cancer (IARC) has resulted in classifying many substances, including pharmaceuticals, as probably or possibly carcinogenic to humans, based on experiments on animals or limited data on humans. We evaluated 9 such pharmaceuticals for evidence of carcinogenicity in patients receiving them in a large medical care program with automated pharmacy records and a cancer registry. Nested case–control analyses were performed in a cohort of 6.5 million subscribers with up to 12 years of follow‐up, focusing on cancer sites suggested by previous evidence and other sites with odds ratio of at least 1.50, p < 0.01 and some evidence of dose–response. Unmeasured confounding was estimated in sensitivity analyses. We found some supportive evidence for carcinogenicity of griseofulvin, metronidazole and phenytoin and for the known carcinogen, cyclophosphamide, which was added for validation of our data and analyses. Findings for chloramphenicol, iron‐dextran complex, phenoxybenzamine and phenobarbital were essentially non‐contributory. Confounding by cigarette smoking and prior thyroid disease could account, respectively, for associations of oxazepam with lung cancer and propylthiouracil with thyroid cancer. Although not definitive, these findings should be considered in the evaluations of these pharmaceuticals. © 2009 UICC
- 27 April 2009
- Published by Wiley in International Journal of Cancer
- Vol. 125 (9) , 2173-2178
Open AccessEpidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity
Thorough review by the International Agency for Research on Cancer (IARC) has resulted in classifying many substances, including pharmaceuticals, as probably or possibly carcinogenic to humans, based on experiments on animals or limited data on humans. We evaluated 9 such pharmaceuticals for evidence of carcinogenicity in patients receiving them in a large medical care program with automated pharmacy records and a cancer registry. Nested case–control analyses were performed in a cohort of 6.5 million subscribers with up to 12 years of follow‐up, focusing on cancer sites suggested by previous evidence and other sites with odds ratio of at least 1.50, p < 0.01 and some evidence of dose–response. Unmeasured confounding was estimated in sensitivity analyses. We found some supportive evidence for carcinogenicity of griseofulvin, metronidazole and phenytoin and for the known carcinogen, cyclophosphamide, which was added for validation of our data and analyses. Findings for chloramphenicol, iron‐dextran complex, phenoxybenzamine and phenobarbital were essentially non‐contributory. Confounding by cigarette smoking and prior thyroid disease could account, respectively, for associations of oxazepam with lung cancer and propylthiouracil with thyroid cancer. Although not definitive, these findings should be considered in the evaluations of these pharmaceuticals. © 2009 UICC
- 16 July 2008
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 116 (1) , 187-194
Pharmaceuticals that cause mammary gland tumors in animals: findings in women
Risk of breast cancer in women was assessed for eight pharmaceuticals that produce mammary tumors in experimental animals, using nested case–control analyses in two cohorts with prescription records in a comprehensive medical care program. The two cohorts were: (1) earlier cohort: 78,118 female members who received prescriptions in 1969–1973, of whom 2,467 developed breast cancer, and (2) later cohort: 3,289,408 female members who received prescriptions in 1994–2006 of whom 24,528 developed breast cancer. Longest follow-up was until June 30, 2006. Ten randomly selected concurrent control women were age-matched to almost every case. Relative risks were estimated by conditional logistic regression. Case ascertainment was lagged by 2 years, or unlagged and subdivided by number of prescriptions received. Some analyses were controlled for hormone use and sensitivity analyses were conducted to estimate the effects of uncontrolled confounding. In the later cohort furosemide, and metronidazole showed statistically significant but very small increases in relative risk (ranging from 1.07 to 1.13). Of these, only furosemide showed increased risk in the earlier cohort: 2-year lag relative risk 1.66 (95% confidence interval 1.23–2.24) or as low as 0.97, assuming uncontrolled positive confounding. Griseofulvin showed significant increases in the later cohort: relative risk for three or more prescriptions 1.48 (1.08–2.03) or as low as 1.23 assuming uncontrolled positive confounding and non-significant increases were noted in the earlier cohort. Our findings are limited by their inconsistency across the two cohorts and our inability to directly control for most established breast cancer risk factors. Although inconclusive, our findings suggest a need for more research on furosemide and griseofulvin.
- 16 July 2008
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 116 (1) , 187-194
Pharmaceuticals that cause mammary gland tumors in animals: findings in women
Risk of breast cancer in women was assessed for eight pharmaceuticals that produce mammary tumors in experimental animals, using nested case–control analyses in two cohorts with prescription records in a comprehensive medical care program. The two cohorts were: (1) earlier cohort: 78,118 female members who received prescriptions in 1969–1973, of whom 2,467 developed breast cancer, and (2) later cohort: 3,289,408 female members who received prescriptions in 1994–2006 of whom 24,528 developed breast cancer. Longest follow-up was until June 30, 2006. Ten randomly selected concurrent control women were age-matched to almost every case. Relative risks were estimated by conditional logistic regression. Case ascertainment was lagged by 2 years, or unlagged and subdivided by number of prescriptions received. Some analyses were controlled for hormone use and sensitivity analyses were conducted to estimate the effects of uncontrolled confounding. In the later cohort furosemide, and metronidazole showed statistically significant but very small increases in relative risk (ranging from 1.07 to 1.13). Of these, only furosemide showed increased risk in the earlier cohort: 2-year lag relative risk 1.66 (95% confidence interval 1.23–2.24) or as low as 0.97, assuming uncontrolled positive confounding. Griseofulvin showed significant increases in the later cohort: relative risk for three or more prescriptions 1.48 (1.08–2.03) or as low as 1.23 assuming uncontrolled positive confounding and non-significant increases were noted in the earlier cohort. Our findings are limited by their inconsistency across the two cohorts and our inability to directly control for most established breast cancer risk factors. Although inconclusive, our findings suggest a need for more research on furosemide and griseofulvin.
- 18 October 2007
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 17 (1) , 27-36
Screening statins for possible carcinogenic risk: up to 9 years of follow‐up of 361 859 recipients
Purpose: Determine the risk of cancer in statin users.Methods: Risk of cancer in up to 9.4 years after first recorded receipt of statins was evaluated in subscribers of an integrated health care program in northern California. Statin use and cancer development were ascertained from the program's pharmacy records and cancer registry from August 1994 to December 2003.Results: Most of the 361 859 statin users received lovastatin, simvastatin or both. Results are presented from analyses with 2‐year lag and use for over 5 years. Most of the observed associations were likely due to chance or confounding. The few associations that seemed less readily explainable were increased risk of cancers of the thyroid, esophagus and urinary tract and decreased risk of colon cancer in men. Increased risk of lung cancer was the only nominally statistically significant positive association in women and could be partially attributable to their smoking habits.Conclusions: Overall this study provided no strong evidence of either causation or prevention of cancer by statins. Copyright © 2007 John Wiley & Sons, Ltd.
- 18 October 2007
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 17 (1) , 27-36
Screening statins for possible carcinogenic risk: up to 9 years of follow‐up of 361 859 recipients
Purpose: Determine the risk of cancer in statin users.Methods: Risk of cancer in up to 9.4 years after first recorded receipt of statins was evaluated in subscribers of an integrated health care program in northern California. Statin use and cancer development were ascertained from the program's pharmacy records and cancer registry from August 1994 to December 2003.Results: Most of the 361 859 statin users received lovastatin, simvastatin or both. Results are presented from analyses with 2‐year lag and use for over 5 years. Most of the observed associations were likely due to chance or confounding. The few associations that seemed less readily explainable were increased risk of cancers of the thyroid, esophagus and urinary tract and decreased risk of colon cancer in men. Increased risk of lung cancer was the only nominally statistically significant positive association in women and could be partially attributable to their smoking habits.Conclusions: Overall this study provided no strong evidence of either causation or prevention of cancer by statins. Copyright © 2007 John Wiley & Sons, Ltd.
- Open Access
- 1 November 2006
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 15 (11) , 2102-2106
Antibiotics and Risk of Breast Cancer: Up to 9 Years of Follow-up of 2.1 Million Women
Antibiotic use has been associated with risk of breast cancer in previous reports. Using Cox proportional hazards analysis, we evaluated this association in 2,130,829 adult female subscribers of a health care program according to their receipt of prescriptions of antibiotics from outpatient pharmacies. Hormone use was taken into account. Altogether, 18,521 women developed breast cancer in up to 9.4 years of follow-up. Use of any antibiotic was associated with slightly increased risk [hazard ratio (HR), 1.14; 95% confidence interval (95% CI), 1.10-1.18] but there was little, if any, evidence of dose response, with HR of 1.17 (95% CI, 0.97-1.42) for >1,000 days of use compared with no use. The only two weakly associated antibiotic groups (HR >1.10 for >100 days of use) were tetracyclines and macrolides with HRs (95% CI) of 1.23 (1.11-1.36) and 1.16 (0.98-1.36), respectively. An association of lincosamides with breast cancer in an earlier, smaller database was not confirmed, but follow-up was too short in the present data for adequate evaluation. Medical record review suggested that acne and/or rosacea could be the underlying factor, associated with long-term antibiotic therapy and found by others to be associated with risk of breast cancer. Although causality cannot be ruled out, the observed associations of antibiotics overall, tetracyclines, and macrolides with breast cancer were weak and could be explained by uncontrolled confounding by the diseases being treated or by other factors. (Cancer Epidemiol Biomarkers Prev 2006;15(11):2102–6)
- 1 November 2006
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 15 (11) , 2102-2106
Open AccessAntibiotics and Risk of Breast Cancer: Up to 9 Years of Follow-up of 2.1 Million Women
Antibiotic use has been associated with risk of breast cancer in previous reports. Using Cox proportional hazards analysis, we evaluated this association in 2,130,829 adult female subscribers of a health care program according to their receipt of prescriptions of antibiotics from outpatient pharmacies. Hormone use was taken into account. Altogether, 18,521 women developed breast cancer in up to 9.4 years of follow-up. Use of any antibiotic was associated with slightly increased risk [hazard ratio (HR), 1.14; 95% confidence interval (95% CI), 1.10-1.18] but there was little, if any, evidence of dose response, with HR of 1.17 (95% CI, 0.97-1.42) for >1,000 days of use compared with no use. The only two weakly associated antibiotic groups (HR >1.10 for >100 days of use) were tetracyclines and macrolides with HRs (95% CI) of 1.23 (1.11-1.36) and 1.16 (0.98-1.36), respectively. An association of lincosamides with breast cancer in an earlier, smaller database was not confirmed, but follow-up was too short in the present data for adequate evaluation. Medical record review suggested that acne and/or rosacea could be the underlying factor, associated with long-term antibiotic therapy and found by others to be associated with risk of breast cancer. Although causality cannot be ruled out, the observed associations of antibiotics overall, tetracyclines, and macrolides with breast cancer were weak and could be explained by uncontrolled confounding by the diseases being treated or by other factors. (Cancer Epidemiol Biomarkers Prev 2006;15(11):2102–6)
- Open Access
- 17 June 2005
- Published by Oxford University Press (OUP) in Family Practice
- Vol. 22 (5) , 548-553
Early symptoms of ovarian cancer: a case–control study without recall bias
Background. Ovarian cancer is usually diagnosed after it has spread and is difficult to cure. Previous attempts to identify early symptoms have either lacked a control group or have been based on interviews of cases, with possible recall bias. Objective. The purpose of this study was to identify early symptoms of ovarian cancer by reviewing prediagnostic medical records, free of recall bias, and comparing women with and without ovarian cancer. Methods. In an integrated health care delivery system, symptoms recorded in medical records of 102 women with ovarian cancer during the two years before diagnosis were compared with those of 102 matched control women. Results. More cases than controls complained of several symptoms up to one year before diagnosis. Most of these symptoms were abdominal or gastrointestinal in nature and were more prevalent in the advanced stage cases. Other symptom sites included pelvic, urinary, back, and systemic. Because case–control differences were not large and prevalence is low, positive predictive values were generally quite low. Conclusion. Previous reports of early symptoms of ovarian cancer were confirmed in a study with a control group and free of recall bias. It is not clear that these symptoms occurred while the disease was still localized. Because hundreds of women would have to be investigated to detect one case of ovarian cancer, the clinical utility of these symptoms is uncertain. Nevertheless, health care providers should keep ovarian cancer in mind, when women present with symptoms such as abdominal pain and bloating.
- 17 June 2005
- Published by Oxford University Press (OUP) in Family Practice
- Vol. 22 (5) , 548-553
Open AccessEarly symptoms of ovarian cancer: a case–control study without recall bias
Background. Ovarian cancer is usually diagnosed after it has spread and is difficult to cure. Previous attempts to identify early symptoms have either lacked a control group or have been based on interviews of cases, with possible recall bias. Objective. The purpose of this study was to identify early symptoms of ovarian cancer by reviewing prediagnostic medical records, free of recall bias, and comparing women with and without ovarian cancer. Methods. In an integrated health care delivery system, symptoms recorded in medical records of 102 women with ovarian cancer during the two years before diagnosis were compared with those of 102 matched control women. Results. More cases than controls complained of several symptoms up to one year before diagnosis. Most of these symptoms were abdominal or gastrointestinal in nature and were more prevalent in the advanced stage cases. Other symptom sites included pelvic, urinary, back, and systemic. Because case–control differences were not large and prevalence is low, positive predictive values were generally quite low. Conclusion. Previous reports of early symptoms of ovarian cancer were confirmed in a study with a control group and free of recall bias. It is not clear that these symptoms occurred while the disease was still localized. Because hundreds of women would have to be investigated to detect one case of ovarian cancer, the clinical utility of these symptoms is uncertain. Nevertheless, health care providers should keep ovarian cancer in mind, when women present with symptoms such as abdominal pain and bloating.
Cryptococcosis: the 1981–2000 epidemic
Summary: The annual incidence of cryptococcosis during 1981–2000 was determined in subscribers of a large integrated health care program in Northern California and in those among them who were HIV positive. The incidence of cryptococcosis had been measured in this setting in the previous decade. The 20‐year incidence per million person‐years was 19.0 in males and 2.6 in females. In males, annual incidence rose sharply but irregularly from 1981 to 1992, then decreased irregularly. In females, trends were less marked, with maximum incidence in 1997. In HIV‐positive patients cryptococcosis incidence was highest in 1981–85 and decreased thereafter in men. In women, maximum incidence occurred in 1986–90 and was followed by a decrease. Cryptococcosis was rare in the non‐predisposed. Thus, cryptococcosis incidence increased markedly in men early in the AIDS epidemic, and began to decrease in both male and female HIV‐positive patients well before highly active antiretroviral therapy became available.
Cryptococcosis: the 1981–2000 epidemic
Summary: The annual incidence of cryptococcosis during 1981–2000 was determined in subscribers of a large integrated health care program in Northern California and in those among them who were HIV positive. The incidence of cryptococcosis had been measured in this setting in the previous decade. The 20‐year incidence per million person‐years was 19.0 in males and 2.6 in females. In males, annual incidence rose sharply but irregularly from 1981 to 1992, then decreased irregularly. In females, trends were less marked, with maximum incidence in 1997. In HIV‐positive patients cryptococcosis incidence was highest in 1981–85 and decreased thereafter in men. In women, maximum incidence occurred in 1986–90 and was followed by a decrease. Cryptococcosis was rare in the non‐predisposed. Thus, cryptococcosis incidence increased markedly in men early in the AIDS epidemic, and began to decrease in both male and female HIV‐positive patients well before highly active antiretroviral therapy became available.